Actively Recruiting
Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis
Led by Kafrelsheikh University · Updated on 2024-08-13
200
Participants Needed
1
Research Sites
116 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Along with the current clinical trial, the efficacy and safety of a 150 mg Bid dabigatran administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to 20 mg rivaroxaban were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral hemorrhagic complications
CONDITIONS
Official Title
Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 and above
- New diagnosis of symptomatic cerebral venous thrombosis confirmed by CT/CT venogram or MRI/MR venogram
- Ability to start treatment within 14 days of confirmed diagnosis
- Treating clinician agrees that oral anticoagulation is appropriate
- Patient or legally authorized representative can provide written informed consent
You will not qualify if you...
- Known antiphospholipid antibody syndrome with prior venous or arterial thrombosis
- Expected need for invasive procedures before starting oral anticoagulation
- Unable to swallow due to lowered consciousness
- Severe kidney impairment (Creatinine clearance less than 30 mL/min)
- Pregnancy or positive pregnancy test in women of childbearing potential
- Breastfeeding at time of randomization
- Bleeding disorders or other reasons preventing anticoagulation
- Medical conditions requiring mandatory use of other blood thinners or antiplatelets
- Use of strong CYP3A4 enzyme inducers or inhibitors
- Severe or fatal illness preventing improvement
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kafr Elsheikh University Hospital
Kafr ash Shaykh, Egypt, 33511
Actively Recruiting
Research Team
M
mohamed G. Zeinhom, MD
CONTACT
S
sherihan R. ahmed, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here